Monitoring treatment and escalation therapy in multiple sclerosis

A disease modifying treatment should be given as quickly as possible when remittent multiple sclerosis. In case of evolution of the disease despite treatment, do not hesitate to switch to a second-line treatment.

Patrick Vermersch reports consulting fees from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche, Servier, Celgene, MedDay, Almirall, and research supports from Biogen, Novartis, Sanofi-Genzyme, Roche and Merck.